The results with the tryptamine and the quinoline pan-SHIP1/2 inhibitors provide good evidence that SHIP inhibition may be utilized as a molecular mechanism to treat a number of cancer types, and more work in this area appears warranted given the need for new cancer therapeutics with novel molecular mechanisms, and particularly those that also target the PI3K-AKT pathway essential for survival of virtually all forms of cancer. This evidence concerns the gene AKT1 and cancer.